The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome*

References

• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–1885.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–543.
   PubMed Web of Science ®Google Scholar
• Falantes J, Calderón C, Márquez-Malaver FJ, et al. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with less than 10% bone marrow blasts and non unfavorable cytogenetic categories. Clin Lymphoma Myeloma Leuk. 2013;13:144–152.
   PubMed Web of Science ®Google Scholar
• Falantes J, Garcia-Manero G. Does the concenpt of lower-risk myelodysplastic syndrome need to be revisited? Leuk Res. 2015;39:1003–1005.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Porta MGD, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441–449.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HTC)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–4254.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29:2240–2246.
   PubMed Web of Science ®Google Scholar
• Breccia M, Federico V, Latagliata R, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35:159–162.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Halene S, et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009;33:1594–1598.
   PubMed Web of Science ®Google Scholar
• Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21:114–119.
   PubMed Web of Science ®Google Scholar
• Fega KR, Abel GA, Motyckova G, et al. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015;6:288–298.
   PubMed Web of Science ®Google Scholar
• Zipperer E, Tanha N, Strupp C, et al. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica. 2014;99:e31–e32.
   PubMed Web of Science ®Google Scholar
• Daver N, Naqvi K, Jabbour E, et al. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014;89:509–516.
   PubMed Web of Science ®Google Scholar
• Balleari E, Salvetti C, Corso LD, et al. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leuk Res. 2015;39:846–852.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–829.
   PubMed Web of Science ®Google Scholar
• Van Spronsen MF, Ossenkoppele GJ, Holman R, et al. Improved risk stratification by the integration of the revised International Prognostic Scoring System with the Myelodysplastic Syndromes Comorbidity Index. Eur J Cancer. 2014;50:3198–3205.
   PubMed Web of Science ®Google Scholar
• Bernabeu-Wittel M, Murcia-Zaragoza J, Hernández-Quiles C, et al. Development of a six-month prognostic index in patients with advanced chronic medical conditions: the PALIAR score. J Pain Symptom Manage. 2014;47:551–565.
   Google Scholar
• Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174:88–101.
   PubMed Web of Science ®Google Scholar
• Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe E, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennet J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Falantes J, Delgado RG, Calderón-Cabrera C, et al. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leuk Res. 2015;39:52–57.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585.
   PubMed Web of Science ®Google Scholar
• Gray RJA. Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
   Web of Science ®Google Scholar
• Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116:2174–2179.
   PubMed Web of Science ®Google Scholar